Table III.
Serum levels of AFU and AFP in various liver diseases and normal control subjects.
| AFU (μmol/l h)
|
AFP (μg/l)
|
||||||||
|---|---|---|---|---|---|---|---|---|---|
| Groups | n | Mean ± SD | Fa | P-valuea | ≥636.5 (%) | Median (range) | Zb | P-valueb | ≥44.0 (%) |
| HCC | 113 | 726.4±258.4 | 64 (56.6)c | 321.1 (0.7–10000.0) | 67 (59.3)c | ||||
| LC | 51 | 562.7±208.6 | −163.71 | 0.001 | 15 (29.4) | 7.3 (0.4–860.7) | 4.723 | 0.000 | 14 (27.5) |
| CH | 21 | 554.4±222.4 | −172.01 | 0.021 | 3 (14.3) | 14.2 (0.7–240.3) | 4.839 | 0.000 | 5 (23.8) |
| NC | 30 | 382.4±133.0 | −344.05 | 0.000 | 0 (0.0) | 2.3 (0.2–9.7) | 5.898 | 0.000 | 0 (0.0) |
a
F and P-values were calculated by F-tests;
b
Z and P-values were calculated by rank-sum tests;
c
P<0.05 and calculated by Chi-square or Fisher’s exact tests, while the HCC group was compared with the other groups. AFU, α-L-fucosidase; AFP, α-fetoprotein; HCC, hepatocellular carcinoma; LC, liver cirrhosis; CH, chronic viral hepatitis; NC, normal control.